Meta Falls, Chipotle Plunges, Eli Lilly Jumps
On this episode of Stock Movers:- Eli Lilly (LLY) raised its full-year guidance as revenue from its weight loss and diabetes drugs beat expectations in the third quarter. The company's diabetes drug Mounjaro and obesity treatment Zepbound outpaced expectations by a combined nearly $1.3 billion, with the vast majority of the beat coming from the diabetes drug. Lilly now expects full-year sales of $63 billion to $63.5 billion and adjusted earnings per share of $23 to $23.70, after sales in the third quarter were $17.6 billion, exceeding the average Wall Street estimate.- Chipotle (CMG) shares…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.